Cargando…

P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Yang, Fan, Liu, Rui, Fu, Zhonghua, Xu, Teng, Zheng, Peihao, Feng, Shaomei, Guo, Yuelu, MA, Lixia, Shi, Hui, Deng, Biping, Ke, Xiaoyan, Hu, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431088/ http://dx.doi.org/10.1097/01.HS9.0000971588.68510.b0

Ejemplares similares

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

Polatuzumab vedotin for B-cell lymphoma
Publicado: (2020)

The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma
por: Xue, Fei, et al.
Publicado: (2022)

P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.
por: Guo, Yuelu, et al.
Publicado: (2023)

Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
por: Shemesh, Colby S., et al.
Publicado: (2020)

PB2101: A PROSPECTIVE INVESTIGATION INTO THE TIMING AND STATUS OF BCMA-CART IN SECONDARY PLASMA CELL LEUKEMIA
por: Guo, Yuelu, et al.
Publicado: (2023)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Correction to: Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Excellent Interim Treatment Response with Polatuzumab Vedotin
por: Mehtap, Özgür, et al.
Publicado: (2020)

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022)

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
por: Alanzi, Meshaal, et al.
Publicado: (2023)

Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
por: Major, Ajay, et al.
Publicado: (2022)

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
por: Thomas, Colin, et al.
Publicado: (2023)

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA
por: Su, Guoai, et al.
Publicado: (2023)

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients
por: Douglas, Melanie
Publicado: (2020)

Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
por: Assi, Rita, et al.
Publicado: (2021)

Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
por: Dere, Randall C., et al.
Publicado: (2023)

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL
por: Zheng, Peihao, et al.
Publicado: (2023)

Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
por: Anderson, Kara, et al.
Publicado: (2020)

Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?
por: Davis, James A., et al.
Publicado: (2023)

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
por: Topp, Max S., et al.
Publicado: (2022)

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022)

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2019)

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma
por: Terui, Yasuhito, et al.
Publicado: (2021)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases
por: Gerhardt, Kristin, et al.
Publicado: (2021)

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL
por: Shi, Hui, et al.
Publicado: (2022)

Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
por: Abdur Raqib, Moosa, et al.
Publicado: (2023)

A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma
por: Liu, Yanyan, et al.
Publicado: (2022)

Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
por: Saburi, Masuho, et al.
Publicado: (2023)

Time‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
por: Lu, D, et al.
Publicado: (2017)

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
por: Song, Yuqin, et al.
Publicado: (2023)

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
por: Shi, Rong, et al.
Publicado: (2020)

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
por: Dal, Mehmet Sinan, et al.
Publicado: (2022)

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
por: Northend, Michael, et al.
Publicado: (2022)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vq3t0fdogr9a2d793p440ckesn